Tumor dormancy and the neuroendocrine system: An undisclosed connection?

Cancer and Metastasis Reviews

Volumn 32, Issue 1-2, 2013, Pages 189-200

  Zappalà, Giovanna ^a,f   McDonald, Paige Green ^b   Cole, Steve W ^c,d,e  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAIC FREDERICK INC   (United States)

Author keywords

Cancer recurrence; Immunosurveillance; Neuroendocrine system; Tumor dormancy; Tumor microenvironment

Indexed keywords

ADAPTATION; ADAPTIVE STRESS RESPONSE; ADRENERGIC SYSTEM; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; METASTASIS; MOLECULAR MECHANICS; NEUROENDOCRINE SYSTEM; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; STRESS; TUMOR CELL; TUMOR DORMANCY; TUMOR MICROENVIRONMENT;

HUMANS; NEOPLASM STAGING; NEOPLASMS; NEUROSECRETORY SYSTEMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84878112459     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9400-x     Document Type: Review

References (87)

1. Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews. Cancer, 7(11), 834-846. doi: 10.1038/nrc2256.
2. Antoni, M. H., Lutgendorf, S. K., Cole, S. W., Dhabhar, F. S., Sephton, S. E., McDonald, P. G., et al. (2006). The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nature Reviews. Cancer, 6(3), 240-248. doi: 10.1038/nrc1820.
3. Irwin, M. R., & Cole, S. W. (2011). Reciprocal regulation of the neural and innate immune systems. Nature Reviews Immunology, 11(9), 625-632. doi: 10.1038/nri3042.
4. Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., et al. (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine, 12(8), 939-944. doi: 10.1038/nm1447.
5. Lutgendorf, S. K., Cole, S., Costanzo, E., Bradley, S., Coffin, J., Jabbari, S., et al. (2003). Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clinical Cancer Research, 9(12), 4514-4521.
6. Yang, E. V., Sood, A. K., Chen, M., Li, Y., Eubank, T. D., Marsh, C. B., et al. (2006). Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Research, 66(21), 10357-10364. doi: 10.1158/0008-5472.CAN-06-2496.
7. Nilsson, M. B., Armaiz-Pena, G., Takahashi, R., Lin, Y. G., Trevino, J., Li, Y., et al. (2007). Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. Journal of Biological Chemistry, 282(41), 29919-29926. doi: 10.1074/jbc.M611539200.
8. Shahzad, M. M., Arevalo, J. M., Armaiz-Pena, G. N., Lu, C., Stone, R. L., Moreno-Smith, M., et al. (2010). Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. Journal of Biological Chemistry, 285(46), 35462-35470. doi: 10.1074/jbc.M110.109579.
9. Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., et al. (2006). Stress hormone-mediated invasion of ovarian cancer cells. Clinical Cancer Research, 12(2), 369-375. doi: 10.1158/1078-0432.CCR-05-1698.
10. Fang, C. Y., Miller, S. M., Bovbjerg, D. H., Bergman, C., Edelson, M. I., Rosenblum, N. G., et al. (2008). Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia. Annals of Behavioral Medicine, 35(1), 87-96. doi: 10.1007/s12160-007-9007-6.
11. Yang, E. V., & Glaser, R. (2003). Stress-induced immunomodulation: implications for tumorigenesis. Brain, Behavior, and Immunity, 17(Suppl 1), S37-S40.
12. Black, P. H. (2002). Stress and the inflammatory response: a review of neurogenic inflammation. Brain, Behavior, and Immunity, 16(6), 622-653.
13. Garcia-Bueno, B., Caso, J. R., & Leza, J. C. (2008). Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neuroscience and Biobehavioral Reviews, 32(6), 1136-1151. doi: 10.1016/j.neubiorev.2008.04.001.
14. Black, W. C., & Welch, H. G. (1993). Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. The New England Journal of Medicine, 328(17), 1237-1243. doi: 10.1056/ NEJM199304293281706.
15. Nielsen, M., Thomsen, J. L., Primdahl, S., Dyreborg, U., & Andersen, J. A. (1987). Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. British Journal of Cancer, 56(6), 814-819.
16. Harach, H. R., Franssila, K. O., & Wasenius, V. M. (1985). Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer, 56(3), 531-538.
17. Montie, J. E., Wood, D. P., Jr., Pontes, J. E., Boyett, J. M., & Levin, H. S. (1989). Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer, 63(2), 381-385.
18. Kimura, W., Morikane, K., Esaki, Y., Chan, W. C., & Pour, P. M. (1998). Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy. Cancer, 82(10), 1839-1849. doi: 10.1002/(SICI)1097-0142.
19. Folkman, J., & Kalluri, R. (2004). Cancer without disease. Nature, 427(6977), 787. doi: 10.1038/427787a.
20. Pantel, K., Alix-Panabieres, C., & Riethdorf, S. (2009). Cancer micrometastases. Nature Reviews. Clinical Oncology, 6(6), 339-351. doi: 10.1038/nrclinonc.2009.44.
21. Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. The New England Journal of Medicine, 353(8), 793-802. doi: 10.1056/NEJMoa050434.
22. Janni, W. J., Vogl, F. D., Wiedswang, G., Synnestvedt, M., Fehm, T. N., Jueckstock, J., et al. (2011). Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a European pooled analysis. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR- 10-2515.
23. Rahbari, N. N., Aigner, M., Thorlund, K., Mollberg, N., Motschall, E., Jensen, K., et al. (2010). Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology, 138(5), 1714-1726. doi: 10.1053/j.gastro.2010.01.008.
24. Mocellin, S., Hoon, D., Ambrosi, A., Nitti, D., & Rossi, C. R. (2006). The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clinical Cancer Research, 12(15), 4605-4613. doi: 10.1158/1078-0432.CCR-06-0823.
25. Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., et al. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research, 10(24), 8152-8162. doi: 10.1158/1078-0432. CCR-04-1110.
26. Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews. Cancer, 9(4), 302-312. doi: 10.1038/nrc2627.
27. Eyles, J., Puaux, A. L., Wang, X., Toh, B., Prakash, C., Hong, M., et al. (2010). Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. The Journal of Clinical Investigation, 120(6), 2030-2039. doi: 10.1172/JCI42002.
28. Potter, J. D. (2007). Morphogens, morphostats, microarchitecture and malignancy. Nature Reviews. Cancer, 7(6), 464-474. doi: 10.1038/nrc2146.
29. Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., et al. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. The Journal of Cell Biology, 137(1), 231-245.
30. Soto, A. M., & Sonnenschein, C. (2004). The somatic mutation theory of cancer: growing problems with the paradigm? Bioessays, 26(10), 1097-1107. doi: 10.1002/bies.20087.
31. Aguirre Ghiso, J. A., Kovalski, K., & Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. The Journal of Cell Biology, 147(1), 89-104.
32. Aguirre Ghiso, J. A. (2002). Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene, 21(16), 2513-2524. doi: 10.1038/sj.onc.1205342.
33. Barkan, D., Kleinman, H., Simmons, J. L., Asmussen, H., Kamaraju, A. K., Hoenorhoff, M. J., et al. (2008). Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research, 68(15), 6241-6250. doi: 10.1158/0008-5472.CAN-07-6849.
34. Barkan, D., El Touny, L. H., Michalowski, A. M., Smith, J. A., Chu, I., Davis, A. S., et al. (2010). Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Research, 70(14), 5706-5716. doi: 10.1158/0008-5472.CAN-09-2356.
35. Shibue, T., & Weinberg, R. A. (2009). Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proceedings of the National Academy of Sciences of the United States of America, 106(25), 10290-10295. doi: 10.1073/pnas. 0904227106.
36. White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., et al. (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell, 6(2), 159-170. doi: 10.1016/j.ccr.2004.06. 025.
37. Jodele, S., Blavier, L., Yoon, J. M., & DeClerck, Y. A. (2006). Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Reviews, 25(1), 35-43. doi: 10.1007/s10555-006-7887-8.
38. McCawley, L. J., & Matrisian, L. M. (2001). Matrix metalloproteinases: they're not just for matrix anymore! Current Opinion in Cell Biology, 13(5), 534-540.
39. Heljasvaara, R., Nyberg, P., Luostarinen, J., Parikka, M., Heikkila, P., Rehn, M., et al. (2005). Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Experimental Cell Research, 307(2), 292-304. doi: 10.1016/j.yexcr.2005.03.021.
40. Pozzi, A., Moberg, P. E., Miles, L. A., Wagner, S., Soloway, P., & Gardner, H. A. (2000). Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proceedings of the National Academy of Sciences of the United States of America, 97(5), 2202-2207. doi: 10.1073/pnas.040378497.
41. Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., et al. (2010). The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Research, 70(18), 7042-7052. doi: 10.1158/0008-5472.CAN-10-0522.
42. Udagawa, T., Fernandez, A., Achilles, E. G., Folkman, J., & D'Amato, R. J. (2002). Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. The FASEB Journal, 16(11), 1361-1370. doi: 10.1096/fj.01-0813com.
43. Naumov, G. N., Folkman, J., & Straume, O. (2009). Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clinical & Experimental Metastasis, 26(1), 51-60. doi: 10.1007/s10585-008-9176-0.
44. Naumov, G. N., Akslen, L. A., & Folkman, J. (2006). Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle, 5(16), 1779-1787.
45. Naumov, G. N., Folkman, J., Straume, O., & Akslen, L. A. (2008). Tumor-vascular interactions and tumor dormancy. APMIS, 116(7-8), 569-585. doi: 10.1111/j.1600-0463.2008.01213.x.
46. Indraccolo, S., Minuzzo, S., Masiero, M., Pusceddu, I., Persano, L., Moserle, L., et al. (2009). Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Research, 69(4), 1314-1323. doi: 10.1158/0008-5472.CAN-08-2791.
47. Favaro, E., Amadori, A., & Indraccolo, S. (2008). Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. APMIS, 116(7-8), 648-659. doi: 10.1111/j.1600-0463.2008.01025.x.
48. Guba, M., Cernaianu, G., Koehl, G., Geissler, E. K., Jauch, K. W., Anthuber, M., et al. (2001). A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Research, 61(14), 5575-5579.
49. Holmgren, L., Jackson, G., & Arbiser, J. (1998). p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene, 17(7), 819-824. doi: 10.1038/sj.onc.1201993.
50. Adam, A. P., George, A., Schewe, D., Bragado, P., Iglesias, B. V., Ranganathan, A. C., et al. (2009). Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Research, 69(14), 5664-5672. doi: 10.1158/0008-5472.can-08- 3820.
51. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science, 297(5578), 63-64. doi: 10.1126/science.1073096.
52. Ursini-Siegel, J., Schade, B., Cardiff, R. D., & Muller, W. J. (2007). Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews. Cancer, 7(5), 389-397. doi: 10.1038/nrc2127.
53. Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., et al. (2002). Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell, 2(6), 451-461.
54. Campone, M., Juin, P., Andre, F., & Bachelot, T. (2011). Resistance to HER2 inhibitors: is addition better than substitution? rationale for the hypothetical concept of drug sedimentation. Critical Reviews in Oncology/Hematology, 78(3), 195-205. doi: 10.1016/j.critrevonc.2010.04.012.
55. Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, A., Beer, S., Mandl, S., et al. (2004). MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature, 431(7012), 1112-1117. doi: 10.1038/nature03043.
56. Shachaf, C. M., & Felsher, D. W. (2005). Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Research, 65(11), 4471-4474. doi: 10.1158/0008-5472.CAN-05-1172.
57. Pontier, S. M., & Muller, W. J. (2008). Integrins in breast cancer dormancy. APMIS, 116(7-8), 677-684. doi: 10.1111/j.1600-0463.2008.01026.x.
58. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K., & Ossowski, L. (2001). Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Molecular Biology of the Cell, 12(4), 863-879.
59. Schewe, D. M., & Aguirre-Ghiso, J. A. (2008). ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 105(30), 10519-10524. doi: 10.1073/pnas.0800939105.
60. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 3(11), 991-998. doi: 10.1038/ni1102-991.
61. Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903-907. doi: 10.1038/nature06309.
62. Zhang, B., Zhang, Y., Bowerman, N. A., Schietinger, A., Fu, Y. X., Kranz, D. M., et al. (2008). Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Research, 68(5), 1563-1571. doi: 10.1158/0008-5472.CAN-07-5324.
63. Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., et al. (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 330(6005), 827-830. doi: 10.1126/science.1195300.
64. Cole, S. W., & Sood, A. K. (2012). Molecular pathways: beta-adrenergic signaling in cancer. Clinical Cancer Research, 18(5), 1201-1206. doi: 10.1158/1078-0432.ccr-11-0641.
65. Lutgendorf, S. K., DeGeest, K., Dahmoush, L., Farley, D., Penedo, F., Bender, D., et al. (2011). Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain, Behavior, and Immunity, 25(2), 250-255. doi: 10.1016/j.bbi.2010.10.012.
66. Lutgendorf, S. K., DeGeest, K., Sung, C. Y., Arevalo, J. M., Penedo, F., Lucci, J., 3rd, et al. (2009). Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain, Behavior, and Immunity, 23(2), 176-183. doi: 10.1016/j.bbi.2008.04.155.
67. Lutgendorf, S. K., Johnsen, E. L., Cooper, B., Anderson, B., Sorosky, J. I., Buller, R. E., et al. (2002). Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 95(4), 808-815. doi: 10.1002/cncr.10739.
68. Lutgendorf, S. K., Lamkin, D. M., Jennings, N. B., Arevalo, J. M., Penedo, F., DeGeest, K., et al. (2008). Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clinical Cancer Research, 14(21), 6839-6846. doi: 10.1158/1078-0432.ccr-08-0230.
69. Kiecolt-Glaser, J. K., Stephens, R. E., Lipetz, P. D., Speicher, C. E., & Glaser, R. (1985). Distress and DNA repair in human lymphocytes. Journal of Behavioral Medicine, 8(4), 311-320.
70. Flint, M. S., Baum, A., Chambers, W. H., & Jenkins, F. J. (2007). Induction of DNA damage, alteration of DNA repair and transcriptional activation by stress hormones. Psychoneuroendocrinology, 32(5), 470-479. doi: 10.1016/j.psyneuen.2007.02.013.
71. Hara, M. R., Kovacs, J. J., Whalen, E. J., Rajagopal, S., Strachan, R. T., Grant, W., et al. (2011). A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature, 477(7364), 349-353. doi: 10.1038/nature10368.
72. Feng, Z., Liu, L., Zhang, C., Zheng, T., Wang, J., Lin, M., et al. (2012). Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 109(18), 7013-7018. doi: 10.1073/pnas.1203930109.
73. Shi, M., Liu, D., Duan, H., Qian, L., Wang, L., Niu, L., et al. (2011). The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Research and Treatment, 125(2), 351-362. doi: 10.1007/s10549-010-0822-2.
74. Hartman, Z. C., Yang, X. Y., Glass, O., Lei, G., Osada, T., Dave, S. S., et al. (2011). HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Research, 71(13), 4380-4391. doi: 10.1158/0008-5472.can-11-0308.
75. Simpson, C. D., Anyiwe, K., & Schimmer, A. D. (2008). Anoikis resistance and tumor metastasis. Cancer Letters, 272(2), 177-185. doi: 10.1016/j.canlet.2008.05.029.
76. Sood, A. K., Armaiz-Pena, G. N., Halder, J., Nick, A. M., Stone, R. L., Hu, W., et al. (2010). Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. The Journal of Clinical Investigation, 120(5), 1515-1523. doi: 10.1172/JCI40802.
77. Katori, H., Baba, Y., Imagawa, Y., Nishimura, G., Kagesato, Y., Takagi, E., et al. (2002). Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Letters, 178(2), 151-159.
78. Shintani, T., Komaki, R., Itasaka, S., Isobe, T., Shibuya, K., Wu, W., et al. (2004). Clinical tumor dormancy: biology and regulation of dormant lung metastases in a characterization of the dormant tumor; B16F10 murine melanoma model. AACR Meeting Abstracts, 2004(1), 1139-c-1140.
79. Farrar, J. D., Katz, K. H., Windsor, J., Thrush, G., Scheuermann, R. H., Uhr, J. W., et al. (1999). Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. Journal of Immunology, 162(5), 2842-2849.
80. Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., et al. (2003). VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood, 101(12), 4878-4886. doi: 10.1182/blood-2002-07-1956.
81. Trikha, M., Corringham, R., Klein, B., & Rossi, J. F. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research, 9(13), 4653-4665.
82. Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., et al. (2001). The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain, Behavior, and Immunity, 15(3), 199-226. doi: 10.1006/brbi.2000.0597.
83. Cohen, M., Klein, E., Kuten, A., Fried, G., Zinder, O., & Pollack, S. (2002). Increased emotional distress in daughters of breast cancer patients is associated with decreased natural cytotoxic activity, elevated levels of stress hormones and decreased secretion of Th1 cytokines. International Journal of Cancer, 100(3), 347-354. doi: 10.1002/ijc.10488.
84. Teng, M. W., Swann, J. B., Koebel, C. M., Schreiber, R. D., & Smyth, M. J. (2008). Immune-mediated dormancy: an equilibrium with cancer. Journal of Leukocyte Biology, 84(4), 988-993. doi: 10.1189/jlb.1107774.
85. Biswas, S. K., & Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology, 11(10), 889-896. doi: 10.1038/ni.1937.
86. Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K. (2011). Beta blockers and breast cancer mortality: a population- based study. Journal of Clinical Oncology, 29(19), 2635-2644. doi: 10.1200/jco.2010.33.5422.
87. Powe, D. G., Voss, M. J., Zanker, K. S., Habashy, H. O., Green, A. R., Ellis, I. O., et al. (2010). Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget, 1(7), 628-638.